US Patent 11352361 Compounds useful as RET inhibitors
Patent 11352361 was granted and assigned to Cancer Research Technology Limited on June, 2022 by the United States Patent and Trademark Office.
Currently, there are no issues on this topic.
Find more entities like US Patent 11352361 Compounds useful as RET inhibitors
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
